Sana Biotetechnology diabetes results generates guarded optimism

Final week, Sana Biotechnology, a once-mysterious and still-buzzy biotech startup, launched scientific trial outcomes exhibiting that it had managed to implant insulin-producing cells within the arm muscle of a affected person with kind 1 diabetes with out scary immune rejection.

Past the actual fact that there have been solely outcomes out there for a single affected person, researchers had just one month’s value of followup information at a really low dose. At first blush, the outcomes might need prompted a shrug.

But Sana’s inventory value initially soared 200%. And even when specialists weren’t fairly as exuberant, some acknowledged the corporate and the sector had probably taken an essential step ahead.